Apoptosis, Part II: The role of mutated Fas genes in tumorigenesis

Advances in Clinical Chemistry

Volumn 36, Issue , 2001, Pages

  Maeda, Takahiro ^a   Kamihira, Shimeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FAS ANTIGEN; MESSENGER RNA;

AMINO ACID SEQUENCE; ANIMAL; APOPTOSIS; CELL TRANSFORMATION; GENETICS; HUMAN; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; DNA; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; RNA, MESSENGER;

EID: 0035237153     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0065-2423(01)36026-2     Document Type: Review

References (56)

1. [letter] [see comments] Abdel-Rahman W. Arends M. Morris R. Ramadan M. Wyllie A. Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas Cell Death Differ. 6 1999 387 388
2. Adachi M. Watanabe-Fukunaga R. Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice Proc. Natl. Acad. Sci. U.S.A. 90 1993 1756 1760
3. Bajorath J. Identification of the ligand binding site in Fas (CD95) and analysis of Fas-ligand interactions Proteins 35 1999 475 482
4. Beletskaia I.V. Nazarova L.F. Nikonova L.V. Abbasova S.G. Beletskii I.P. Cell sensitivity to Fas-mediated apoptosis depends on three forms of Fas-antigen Izv. Akad. Nauk., Ser. Biol. 2 1998 187 193
5. Beltinger C. Bohler T. Karawajew L. Ludwig W.D. Schrappe M. Debatin K.M. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia Br. J. Haematol. 102 1998 722 728
6. Beltinger C. Kurz E. Bohler T. Schrappe M. Ludwig W.D. Debatin K.M. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia Blood 91 1998 3943 3951
7. [letter] Bertoni F. Conconi A. Carobbio S. Realini C. Codegoni A.M. Zucca E. Cavalli F. Analysis of Fas/CD95 gene somatic mutations in ovarian cancer cell lines Int. J. Cancer 86 2000 450
8. Bertoni F. Conconi A. Luminari S. Realini C. Roggero E. Baldini L. Carobbio S. Cavalli F. Neri A. Zucca E. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas Leukemia 14 2000 446 448
9. Bettinardi A. Brugnoni D. Quiros-Roldan E. Malagoli A. La Grutta S. Correra A. Notarangelo L.D. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis Blood 89 1997 902 909
10. Cascino I. Fiucci G. Papoff G. Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing J. Immunol. 154 1995 2706 2713
11. Cascino I. Papoff G. De Maria R. Testi R. Ruberti G. Fas/APO-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis J. Immunol. 156 1996 13 17
12. Cheng J. Zhou T. Liu C. Shapiro J.P. Brauer M.J. Kiefer M.C. Barr P.J. Mountz J.D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule Science 263 1994 1759 1762
13. [see comments] Drappa J. Vaishnaw A.K. Sullivan K.E. Chu J.L. Elkon K.B. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity N. Engl. J. Med. 335 1996 1643 1649
14. Fadeel B. Thorpe J. Chiodi F. Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb Int. Immunol. 7 1995 1967 1975
15. Fadeel B. Thorpe C.J. Yonehara S. Chiodi F. Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro Int. Immunol. 9 1997 201 209
16. Fisher G.H. Rosenberg F.J. Straus S.E. Dale J.K. Middleton L.A. Lin A.Y. Strober W. Lenardo M.J. Puck J.M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome Cell 81 1995 935 946
17. Gronbaek K. Straten P.T. Ralfkiaer E. Ahrenkiel V. Andersen M.K. Hansen N.E. Zeuthen J. Hou-Jensen K. Guldberg P. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity Blood 92 1998 3018 3024
18. Haas J.P. Grunke M. Frank C. Kolowos W. Dirnecker D. Leipold G. Hieronymus T. Lorenz H.M. Herrmann M. Increased spontaneous in vitro apoptosis in double negative T cells of humans with a fas/apo-1 mutation Cell Death Differ. 5 1998 751 757
19. Heaney M.L. Golde D.W. Soluble cytokine receptors Blood 87 1996 847 857
20. Huang B. Eberstadt M. Olejniczak E.T. Meadows R.P. Fesik S.W. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain Nature 384 1996 638 641
21. Itoh N. Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen J. Biol. Chem. 268 1993 10932 10937
22. Itoh N. Yonehara S. Ishii A. Yonehara M. Mizushima S. Sameshima M. Hase A. Seto Y. Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis Cell 66 1991 233 243
23. Jenkins M. Keir M. McCune J.M. A membrane-bound Fas decoy receptor expressed by human thymocytes J. Biol. Chem. 275 2000 7988 7993
24. Kamihira S. Yamada Y. Hirakata Y. Tsuruda K. Sugahara K. Tomonaga M. Maeda T. Tsukasaki K. Atogami S. Kobayashi N. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias Br. J. Haematol. 99 1997 858 865
25. Kamihira S. Yamada Y. Tomonaga M. Sugahara K. Tsuruda K. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: Soluble Fas isoform is an independent risk factor for prognosis Br. J. Haematol. 107 1999 851 860
26. Kinoshita K. Kamihira S. Yamada Y. Amagasaki T. Ikeda S. Momita S. Ichimaru M. Adult T-cell leukemia-lymphoma in the Nagasaki district M. Hanaoka K. Takatsuki M. Shimoyama Adult T-Cell Leukemia and Related Disease 1982 Japan Scientific Societies Press New York 167 184
27. Kischkel F.C. Hellbardt S. Behrmann I. Germer M. Pawlita M. Krammer P.H. Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor EMBO J. 14 1995 5579 5588
28. Knipping E. Debatin K.M. Stricker K. Heilig B. Eder A. Krammer P.H. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias Blood 85 1995 1562 1569
29. Landowski T.H. Qu N. Buyuksal I. Painter J.S. Dalton W.S. Mutations in the Fas antigen in patients with multiple myeloma Blood 90 1997 4266 4270
30. Lee S.H. Shin M.S. Kim H.S. Park W.S. Kim S.Y. Jang J.J. Rhim K.J. Jang J. Lee H.K. Park J.Y. Oh R.R. Han S.Y. Lee J.H. Lee J.Y. Yoo N.J. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar J. Invest. Dermatol. 114 2000 122 126
31. Lee S.H. Shin M.S. Park W.S. Kim S.Y. Dong S.M. Pi J.H. Lee H.K. Kim H.S. Jang J.J. Kim C.S. Kim S.H. Lee J.Y. Yoo N.J. Alterations of Fas (APO1/CD95) gene in transitional cell carcinomas of urinary bladder Cancer Res. 59 1999 3068 3072
32. Lee S.H. Shin M.S. Park W.S. Kim S.Y. Kim H.S. Han J.Y. Park G.S. Dong S.M. Pi J.H. Kim C.S. Kim S.H. Lee J.Y. Yoo N.J. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer Oncogene 18 1999 3754 3760
33. Leithauser F. Dhein J. Mechtersheimer G. Koretz K. Bruderlein S. Henne C. Schmidt A. Debatin K.M. Krammer P.H. Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells Lab. Invest. 69 1993 415 429
34. Liu C. Cheng J. Mountz J.D. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation Biochem. J. 310 1995 957 963
35. [see comments] Lynch D.H. Ramsdell F. Alderson M.R. Fas and FasL in the homeostatic regulation of immune responses Immunol. Today 16 1995 569 574
36. Maeda T. Yamada Y. Moriuchi R. Sugahara K. Tsuruda K. JoH T. Atogami S. Tsukasaki K. Tomonaga M. Kamihira S. Fas gene mutation in the progression of adult T cell leukemia J. Exp. Med. 189 1999 1063 1071
37. Martin D.A. Zheng L. Siegel R.M. Huang B. Fisher G.H. Wang J. Jackson C.E. Puck J.M. Dale J. Straus S.E. Peter M.E. Krammer P.H. Fesik S. Lenardo M.J. Defective CD95/PO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type 1a Proc. Natl. Acad. Sci. U.S.A. 96 1999 4552 4557
38. Martin S.J. Apoptosis and cancer: An overview S.J. Martin Apoptosis and Cancer 1997 Karger Lnades System Tokyo 1 8
39. Nagata S. Apoptosis by death factor Cell 88 1997 355 365
40. Nagata S. Golstein P. The Fas death factor Science 267 1995 1449 1456
41. Nagata S. Suda T. Fas and Fas ligand: lpr and gld mutations Immunol. Today 16 1995 9 43
42. Natoli G. Ianni A. Costanzo A. De Petrillo G. Ilari I. Chirillo P. Balsano C. Levrero M. Resistance to Fas-mediated apoptosis in human hepatoma cells Oncogene 11 1995 1157 1164
43. Papoff G. Cascino I. Eramo A. Starace G. Lynch D.H. Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro J. Immunol. 156 1996 4622 4630
44. Peters A.M. Kohfink B. Martin H. Griesinger F. Wormann B. Gahr M. Roesler J. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease Exp. Hematol. 27 1999 868 874
45. Rieux-Laucat F. Le Deist F. Hivroz C. Roberts I.A. Debatin K.M. Fischer A. de Villartay J.P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity Science 268 1995 1347 1349
46. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984–87) Br. J. Haematol. 79 1991 428 437
47. s2 Shin M.S. Park W.S. Kim S.Y. Kim H.S. Kang S.J. Song K.Y. Park J.Y. Dong S.M. Pi J.H. Oh R.R. Lee J.Y. Yoo N.J. Lee S.H. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma Am. J. Pathol. 154 1999 1785 1791
48. Sugahara K. Yamada Y. Hiragata Y. Matsuo Y. Tsuruda K. Tomonaga M. Maeda T. Atogami S. Tsukasaki K. Kamihira S. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines Int. J. Cancer 72 1997 128 132
49. Tachibana O. Nakazawa H. Lampe J. Watanabe K. Kleihues P. Ohgaki H. Expression of Fas/APO-1 during the progression of astrocytomas Cancer Res. 55 1995 5528 5530
50. Tamiya S. Etoh K. Suzushima H. Takatsuki K. Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult Tcell leukemia cells Blood 91 1998 3935 3942
51. Tavernier J. Van der Heyden J. Verhee A. Brusselle G. Van Ostade X. Vandekerckhove J. North J. Rankin S.M. Kay A.B. Robinson D.S. Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit Blood 95 2000 1600 1607
52. Tsuruda K. Yamada Y. Hirakata Y. Sugahara K. Maeda T. Atogami S. Tomonaga M. Kamihira S. Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms Leuk. Res. 23 1999 159 166
53. [published erratum appears in J. Clin. Invest. 103 , 1099 (1999) Vaishnaw A.K. Orlinick J.R. Chu J.L. Krammer P.H. Chao M.V. Elkon K.B. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations J. Clin. Invest. 103 1999 355 363
54. Van Zee K.J. Kohno T. Fischer E. Rock C.S. Moldawer L.L. Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo Proc. Natl. Acad. Sci. U.S.A. 89 1992 4845 4849
55. Von Reyher U. Strater J. Kittstein W. Gschwendt M. Krammer P.H. Moller P. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis Cancer Res. 58 1998 526 534
56. Watanabe-Fukunaga R. Brannan C.I. Copeland N.G. Jenkins N.A. Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis Nature 356 1992 314 317